On Target is a recurring feature from STAT that dives deep into the most promising drug targets in oncology. This column is adapted from a new STAT report, “Targeting cancer: the new frontier of ...

Please provide your email address to receive an email when new articles are posted on . ATLANTA — Intrapleurally administered, mesothelin-targeted chimeric antigen receptor T cells demonstrated ...

Mesothelin is a tumor antigen that is highly expressed in many human cancers, including malignant mesothelioma and pancreatic, ovarian, and lung adenocarcinomas. It is an attractive target for cancer ...

- Preclinical data validate that human T-cells expressing a TCR targeting mesothelin, independent of HLA recognition, can kill human tumor cells - - HiT works as well, or better than, a TRuC construct ...

ImmunoCellular Therapeutics (OTCBB: IMUC) today announced that it has entered into an agreement with The Johns Hopkins University (JHU) under which JHU has granted the Company an exclusive, worldwide ...

Triple-negative breast cancer is one of the most aggressive cancers. The name tells the story: It lacks the three main targets that make other types of breast cancers more treatable with powerful ...

A teenager's innovative paper sensor for early pancreatic cancer detection, based on the protein mesothelin, captured global ...

Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors. ImmunoCellular Therapeutics (OTCBB:IMUC) Wednesday entered into an agreement with Johns Hopkins University which ...

A chimeric antigen receptor (CAR) T-cell therapy that targets the protein mesothelin showed no evidence of major toxicity and had antitumor activity in patients with malignant pleural disease from ...